story of the week
Outcomes of Datopotamab Deruxtecan vs Chemotherapy in Previously Treated Patients With Inoperable/Metastatic HR+/HER2− Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01
J. Clin. Oncol 2024 Sep 12;[EPub Ahead of Print], A Bardia, K Jhaveri, SA Im, S Pernas, M De Laurentiis, S Wang, N Martínez Jañez, G Borges, DW Cescon, M Hattori, YS Lu, E Hamilton, Q Zhang, J Tsurutani, K Kalinsky, PE Rubini Liedke, L Xu, RM Fairhurst, S Khan, N Denduluri, HS Rugo, B Xu, B PistilliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.